Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
NCT05972291

Mechanisms of Gulf War Illness

Led by VA Office of Research and Development · Updated on 2025-12-05

80

Participants Needed

1

Research Sites

197 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Many veterans with Gulf War Illness developed chronic gastrointestinal symptoms during their deployment to the Persian Gulf. The pathophysiologic mechanisms of these chronic gastrointestinal symptoms are not well understood but cause significant morbidity in veterans. Our proposed studies will provide an innovative and novel treatment trial for chronic gastrointestinal symptoms in veterans with Gulf War Illness that were deployed into war zones. Given that there are currently no specific treatments for these disorders, and that current symptomatic approaches are far from ideal, proof of principle of our trial would be an extremely important advance as it would not only have a beneficial impact on the health of many thousands of our veterans, but also it would substantially reduce the many negative economic effects of this ailment on the VA Health Care System.

CONDITIONS

Official Title

Mechanisms of Gulf War Illness

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Veterans aged 18 to 65 years with Gulf War Illness and chronic gastrointestinal symptoms (abdominal pain, diarrhea, bloating) that started during their deployment in the Persian Gulf
  • Veterans aged 18 to 65 years with Gulf War Illness and chronic gastrointestinal symptoms
  • Increased intestinal permeability shown by lactulose/mannitol permeability test (ratio >0.07)
  • Able and willing to cooperate with the study
Not Eligible

You will not qualify if you...

  • Currently participating in another research protocol or unable to give informed consent
  • Women with a positive urine pregnancy test or breastfeeding
  • History of inflammatory bowel disease, lactose intolerance, or celiac sprue
  • Positive hydrogen breath test for bacterial overgrowth
  • Positive anti-endomysial antibody titer
  • Use of NSAIDs within 2 weeks before or during the study
  • Known allergy to glutamine or whey protein
  • Abdominal surgery except removal of gallbladder, uterus, or appendix more than 6 months prior to study entry
  • Abnormal serum blood urea nitrogen (BUN) and/or creatinine levels
  • Mannitol recovery outside the normal range of 5-25 U/g
  • History of kidney disease
  • Allergy to monosodium glutamate
  • Current use of anti-seizure medications

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Memphis VA Medical Center, Memphis, TN

Memphis, Tennessee, United States, 38104-2127

Actively Recruiting

Loading map...

Research Team

G

George N Verne

CONTACT

Q

QiQi Zhou, MD PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here